When to Switch Infliximab in Ulcerative Colitis

Step 1: Define the Type of Failure

• No meaningful benefit after the full induction regimen (5 mg/kg at weeks 0, 2, and 6)
• Should be apparent by the end of induction
• These patients are true non-responders to infliximab; dose escalation is unlikely to help
• Action: Switch mechanism - move to a biologic with a different mechanism (vedolizumab, ustekinumab) rather than another anti-TNF

• Patient had an initial response but subsequently reports diminished benefit
• Estimated at ~13% per year in IBD patients on infliximab
• Risk factors: prior anti-TNF exposure, low serum albumin, lack of concurrent immunomodulator
• Action: Measure trough levels and anti-drug antibodies (ADA) before switching

Step 2: TDM-Guided Decision Algorithm for Secondary LOR

• Yamada's Textbook of Gastroenterology (7th ed), p. 1349-1350, 1393-1394

Step 3: When to Switch Out of Class vs. Within Class

• Immunogenic failure with low or moderate ADA titers (especially if immunomodulator is added)
• Intolerance to IV administration / infusion reactions
• Note from the ULTRA-2 trial: 40% of adalimumab trial patients had prior infliximab loss of response, and adalimumab showed benefit (16.5% vs 9.3% remission at week 8)

• Primary non-response to infliximab
• Pharmacodynamic/true non-response with adequate drug levels
• High-titer ADA with no realistic chance of rescue
• Contraindication to further anti-TNF use (demyelinating disease, moderate-severe heart failure, recurrent serious infections, drug-induced lupus, lymphoma history)
• Tofacitinib is specifically approved only after TNF failure in UC

Step 4: Optimization Before Switching

1. Ensure combination therapy - the UC-SUCCESS trial showed infliximab + azathioprine is superior to monotherapy for remission and endoscopic improvement, and reduces immunogenicity
2. Dose escalation - can increase to 10 mg/kg every 4-8 weeks for secondary LOR with low levels but no ADA
3. Assess concurrent disease triggers - rule out C. difficile, CMV colitis, non-adherence
4. Biomarker reassessment - fecal calprotectin and CRP at 3-monthly intervals; endoscopy at 6-9 months post-initiation to confirm endoscopic activity (not just symptoms)

Important Caveats

• Proactive TDM is not routinely recommended - the TAXIT trial showed no significant improvement in clinical remission rates (69% vs 66%) with proactive drug concentration monitoring vs. clinical-feature-based management, though relapse rates were lower (7% vs 17%). Current guidelines recommend TDM only reactively.
• ADA at low levels may be transient - low-titer antibodies may disappear with continued scheduled dosing or addition of an immunomodulator, and should not automatically prompt switching.
• Assess for active disease objectively - symptoms alone can be misleading (IBS overlap, infection); confirm active inflammation before escalating or switching.

Switching Options After Infliximab Failure in UC

• Yamada's Textbook of Gastroenterology (7th ed), pp. 1337-1354

Evidence: Within-Class TNF Cycling vs. Out-of-Class Mechanism Switch in UC

The Core Principle: Let TDM Guide the Decision

"Patients with sufficient trough levels of the biologic agent will not benefit from continuing or escalating therapy and would benefit most from switching out of therapeutic class to a therapy acting by a different mechanism. Low or undetectable drug levels with high antibody titer should prompt a change to a different anti-TNF agent as there is low cross-reactivity between antibodies."

• Sleisenger and Fordtran's GI and Liver Disease, p. 2345

1. Within-Class Switching (TNF Cycling: infliximab → adalimumab/golimumab)

• Clinical remission at week 52: vedolizumab 20.3% vs adalimumab 16.0% (difference 4.2%; 95% CI -7.8 to 16.2 - not statistically significant)
• Endoscopic improvement: vedolizumab 26.6% vs adalimumab 21.0% (difference 5.5%; 95% CI -7.7 to 18.8 - not significant)
• Corticosteroid-free remission: adalimumab 22.2% vs vedolizumab 4.5% (vedolizumab numerically worse in this subgroup)

• Yamada's Textbook of Gastroenterology (7th ed), p. 1355

2. Out-of-Class Switching: The Evidence Is Stronger

Vedolizumab (anti-α4β7 integrin)

• GEMINI 1 trial: ~47% clinical response at week 6 vs 25.5% placebo. Maintenance remission 42-45% vs 16% placebo at week 52.
• Limitation in TNF-experienced patients: Yamada's explicitly notes "the efficacy of vedolizumab is lower among those with prior anti-TNF failure." This is consistent across trials.
• Considered safer than anti-TNF (no systemic immunosuppression, very low immunogenicity ~5%), making it attractive when anti-TNF safety is a concern (older patients, infection risk, cardiovascular disease).

Ustekinumab (anti-IL-12/23, anti-p40)

• UNIFI trial: Studied 961 UC patients with and without prior anti-TNF exposure. Both TNF-naive and TNF-experienced patients responded, with significantly higher remission rates than placebo at week 8 and 44.
• Network meta-analysis advantage: A NMA of 7 RCTs in 1580 patients with prior TNF exposure found ustekinumab and tofacitinib were ranked highest for inducing clinical remission. Comparing active interventions:
  • Ustekinumab vs adalimumab: OR 10.71 (95% CI 2.01-57.20)
  • Ustekinumab vs vedolizumab: OR 5.99 (95% CI 1.13-31.76)
• Immunogenicity is very low (<5%), an advantage over anti-TNF cycling where re-immunization can occur.
• Yamada's Textbook of Gastroenterology (7th ed), p. 1349, 1353

Tofacitinib (JAK inhibitor - oral)

• Ranked alongside ustekinumab in the NMA for TNF-experienced patients (tofacitinib vs adalimumab: OR 11.05; tofacitinib vs vedolizumab: OR 6.18 for induction remission)
• Approved only after TNF failure in UC
• Concern: increased risk of herpes zoster, thromboembolism at 10 mg BID in older patients with cardiovascular risk factors

3. Real-World Comparative Data (Recent)

• 12-month treatment persistence: switch cohort 79.6% vs cycle cohort 64.9%
• Persistence on monotherapy: 74.6% vs 48.0% (HR 2.56, 95% CI 1.86-3.53)
• Persistence while corticosteroid-free: 60.1% vs 49.3% (HR 1.31, 95% CI 0.98-1.77 - not significant)
• Conclusion: "Patients with UC who switched to a biologic with a different mode of action were more persistent on treatment than patients who cycled to another anti-TNF agent."
• [PMID: 39743427]

• Ustekinumab had superior persistence and colectomy-free survival vs vedolizumab (p=0.02; p=0.05) and tofacitinib (p=0.05; p=0.001), and significantly higher persistence than cycling to another anti-TNF (p<0.001)
• Primary non-response to the first anti-TNF negatively predicted persistence with non-TNF agents (suggesting these patients may have disease biology less responsive to any biologic)
• Hypoalbuminemia increased colectomy risk; concomitant immunomodulator reduced it
• Conclusion: "Switching to a non-anti-TNF agent is worth considering in moderate-to-severe UC after first-line anti-TNF failure."
• [PMID: 40346848]

• 12-month treatment persistence: ustekinumab 93.9%, vedolizumab 87.0%, anti-TNF 75.0% (p<0.001)
• Clinical remission at 12 months: no statistically significant difference between groups (UST 26.9%, VDZ 40.9%, anti-TNF 34.7%; p=0.063)
• Higher persistence with ustekinumab despite similar efficacy - likely reflecting fewer adverse effects and immunogenicity
• [PMID: 40152278]

4. Optimal Sequencing: What the Evidence Suggests

• Yamada's Textbook of Gastroenterology (7th ed), pp. 1349-1356
• Bressler 2023 narrative review on optimal biologic sequencing in IBD (PMID: 37057077)